LifeTech Scientific Corporation (1302) provided supplemental information regarding a connected transaction under its Share Award Scheme. The transaction was initially disclosed in announcements dated 27 June 2024 and 9 December 2025. According to the latest details, the Board considered average closing prices over 30, 60, and 90 consecutive trading days when determining the purchase price of HK$1.90 per share.

The higher price compared to the closing price on the agreement date was attributed to market volatility and a broad pullback in medical device stocks. That same week, the Hang Seng Healthcare Index declined by about 2.30% and underperformed the Hang Seng Index. Daily trading volume for the company’s shares averaged around 30.00 million in 2025, supporting the view that a longer-term price range would better reflect fair value.

For reference, the consideration of HK$1.90 per share represented a 0.11% premium to the five-day average closing price of HK$1.898, and a 1.12% premium to the ten-day average of HK$1.879. The company believes the terms are reasonable and in line with its long-term interests. Under corporate governance measures, no awards related to this scheme will be granted to the executive Director, chairman, and CEO, or his associates, for the remaining duration of the scheme.

Separately, on 13 February 2026, the Board ratified an adjustment of share award limits, reallocating the unused limit of 121.01 million shares from the 2019 Share Award Scheme to the Share Award Scheme. There is no increase to the overall aggregate limit of 896.63 million shares and no issuance of new shares; thus, no dilution arises from this adjustment. The Directors consider the transaction and the adjustments in the best interest of the company and its shareholders as a whole.